YSOTOPE is a Spanish startup founded in 2022 by a team with deep expertise in advanced technology and radiochemistry. The company operates in the healthcare sector, specifically focusing on oncology, which is the study and treatment of cancer. YSOTOPE addresses a significant problem faced by oncologists: the difficulty in tracking CAR T cells in the blood, which is crucial for personalizing cancer treatment.

The company’s solution lies in molecular imaging, a non-invasive technique that provides detailed information about CAR T therapy. YSOTOPE specializes in developing PET radiotracers. These are special compounds used in medical PET (Positron Emission Tomography) scanners to create detailed images of the body at the molecular level. A PET radiotracer consists of three parts: a ligand (a molecule that binds specifically to another molecule), an isotope (a radioactive element used for imaging), and a linker (which connects the ligand to the isotope).

YSOTOPE’s radiotracers are designed to monitor CAR T cells within the body, providing oncologists with critical information to tailor cancer treatments more effectively. This technology is a key component of personalized nuclear medicine and precision oncology, which aim to customize healthcare based on individual patient characteristics.

The company operates on a co-development business model, partnering with research and development (R&D) entities to innovate and refine their products. YSOTOPE ensures the exclusivity of its assets through a combination of intellectual property rights (IPR) tools, including patents. They generate revenue by licensing and sublicensing their patented technologies, as well as by testing their radiopharmaceuticals in both animal and human trials.

In summary, YSOTOPE is pioneering the development of advanced radiotracers to enhance the monitoring and personalization of CAR T cell therapies in cancer treatment.

Keywords: oncology, CAR T cells, molecular imaging, PET radiotracers, personalized medicine, precision oncology, radiochemistry, intellectual property, R&D partnerships, Spain.